nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—UGT1A1—Etoposide—urinary bladder cancer	0.197	0.344	CbGbCtD
Naltrexone—ABCB1—Mitomycin—urinary bladder cancer	0.19	0.332	CbGbCtD
Naltrexone—ABCB1—Gemcitabine—urinary bladder cancer	0.0548	0.0955	CbGbCtD
Naltrexone—ABCB1—Cisplatin—urinary bladder cancer	0.0398	0.0694	CbGbCtD
Naltrexone—ABCB1—Etoposide—urinary bladder cancer	0.0391	0.0682	CbGbCtD
Naltrexone—ABCB1—Doxorubicin—urinary bladder cancer	0.0267	0.0465	CbGbCtD
Naltrexone—ABCB1—Methotrexate—urinary bladder cancer	0.0259	0.045	CbGbCtD
Naltrexone—UGT1A1—urine—urinary bladder cancer	0.0108	0.341	CbGeAlD
Naltrexone—OPRK1—prostate gland—urinary bladder cancer	0.00427	0.135	CbGeAlD
Naltrexone—UGT1A1—prostate gland—urinary bladder cancer	0.00386	0.123	CbGeAlD
Naltrexone—Morphine—UGT2B7—urinary bladder cancer	0.00373	0.719	CrCbGaD
Naltrexone—OPRD1—renal system—urinary bladder cancer	0.00304	0.0963	CbGeAlD
Naltrexone—UGT1A1—renal system—urinary bladder cancer	0.00263	0.0835	CbGeAlD
Naltrexone—OPRK1—female reproductive system—urinary bladder cancer	0.00233	0.074	CbGeAlD
Naltrexone—Naloxone—ESR1—urinary bladder cancer	0.00146	0.281	CrCbGaD
Naltrexone—UGT1A1—Phase II conjugation—UGT2B7—urinary bladder cancer	0.00117	0.0198	CbGpPWpGaD
Naltrexone—UGT1A1—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00115	0.0196	CbGpPWpGaD
Naltrexone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00103	0.0175	CbGpPWpGaD
Naltrexone—ABCB1—prostate gland—urinary bladder cancer	0.000876	0.0278	CbGeAlD
Naltrexone—UGT1A1—Biological oxidations—GSTZ1—urinary bladder cancer	0.000787	0.0134	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000777	0.0132	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000776	0.0132	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000756	0.0129	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—GSTO2—urinary bladder cancer	0.000746	0.0127	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—NAT1—urinary bladder cancer	0.000746	0.0127	CbGpPWpGaD
Naltrexone—ABCB1—seminal vesicle—urinary bladder cancer	0.000741	0.0235	CbGeAlD
Naltrexone—UGT1A1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000735	0.0125	CbGpPWpGaD
Naltrexone—UGT1A1—Phase II conjugation—NAT2—urinary bladder cancer	0.000698	0.0119	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—UGT2B7—urinary bladder cancer	0.000682	0.0116	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000673	0.0114	CbGpPWpGaD
Naltrexone—OPRK1—Mecp2 and Associated Rett Syndrome—NCOR1—urinary bladder cancer	0.000648	0.011	CbGpPWpGaD
Naltrexone—ABCB1—epithelium—urinary bladder cancer	0.000644	0.0204	CbGeAlD
Naltrexone—UGT1A1—Biological oxidations—CYP4B1—urinary bladder cancer	0.000614	0.0104	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000606	0.0103	CbGpPWpGaD
Naltrexone—ABCB1—renal system—urinary bladder cancer	0.000597	0.0189	CbGeAlD
Naltrexone—ABCB1—urethra—urinary bladder cancer	0.000587	0.0186	CbGeAlD
Naltrexone—UGT1A1—Phase II conjugation—HPGDS—urinary bladder cancer	0.000558	0.00949	CbGpPWpGaD
Naltrexone—UGT1A1—Phase II conjugation—GSTT1—urinary bladder cancer	0.000541	0.00921	CbGpPWpGaD
Naltrexone—ABCB1—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000528	0.00898	CbGpPWpGaD
Naltrexone—ABCB1—female reproductive system—urinary bladder cancer	0.000478	0.0152	CbGeAlD
Naltrexone—ABCB1—vagina—urinary bladder cancer	0.000433	0.0137	CbGeAlD
Naltrexone—UGT1A1—Biological oxidations—NAT2—urinary bladder cancer	0.000409	0.00695	CbGpPWpGaD
Naltrexone—UGT1A1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000403	0.00685	CbGpPWpGaD
Naltrexone—UGT1A1—Phase II conjugation—GSTP1—urinary bladder cancer	0.000375	0.00638	CbGpPWpGaD
Naltrexone—UGT1A1—Phase II conjugation—GSTM1—urinary bladder cancer	0.000345	0.00586	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—HPGDS—urinary bladder cancer	0.000327	0.00555	CbGpPWpGaD
Naltrexone—UGT1A1—Biological oxidations—GSTT1—urinary bladder cancer	0.000317	0.00539	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000303	0.00515	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—NQO1—urinary bladder cancer	0.0003	0.0051	CbGpPWpGaD
Naltrexone—OPRM1—TCR Signaling Pathway—FAS—urinary bladder cancer	0.000297	0.00505	CbGpPWpGaD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	0.000293	0.00498	CbGpPWpGaD
Naltrexone—ABCB1—lymph node—urinary bladder cancer	0.00028	0.00888	CbGeAlD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000272	0.00462	CbGpPWpGaD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000264	0.00449	CbGpPWpGaD
Naltrexone—UGT1A1—NRF2 pathway—GSTP1—urinary bladder cancer	0.00025	0.00426	CbGpPWpGaD
Naltrexone—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000243	0.000737	CcSEcCtD
Naltrexone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000243	0.00413	CbGpPWpGaD
Naltrexone—Hepatitis—Methotrexate—urinary bladder cancer	0.000242	0.000733	CcSEcCtD
Naltrexone—Asthenia—Gemcitabine—urinary bladder cancer	0.000241	0.000731	CcSEcCtD
Naltrexone—Pharyngitis—Methotrexate—urinary bladder cancer	0.00024	0.000728	CcSEcCtD
Naltrexone—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000239	0.000723	CcSEcCtD
Naltrexone—Weight increased—Doxorubicin—urinary bladder cancer	0.000238	0.000722	CcSEcCtD
Naltrexone—Epistaxis—Epirubicin—urinary bladder cancer	0.000238	0.000721	CcSEcCtD
Naltrexone—Pruritus—Gemcitabine—urinary bladder cancer	0.000238	0.000721	CcSEcCtD
Naltrexone—Nausea—Thiotepa—urinary bladder cancer	0.000238	0.000719	CcSEcCtD
Naltrexone—Weight decreased—Doxorubicin—urinary bladder cancer	0.000237	0.000718	CcSEcCtD
Naltrexone—Sinusitis—Epirubicin—urinary bladder cancer	0.000237	0.000717	CcSEcCtD
Naltrexone—Feeling abnormal—Etoposide—urinary bladder cancer	0.000237	0.000717	CcSEcCtD
Naltrexone—Pneumonia—Doxorubicin—urinary bladder cancer	0.000235	0.000711	CcSEcCtD
Naltrexone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000235	0.000711	CcSEcCtD
Naltrexone—Pruritus—Fluorouracil—urinary bladder cancer	0.000234	0.000709	CcSEcCtD
Naltrexone—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000234	0.000707	CcSEcCtD
Naltrexone—Infestation—Doxorubicin—urinary bladder cancer	0.000234	0.000707	CcSEcCtD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000232	0.00394	CbGpPWpGaD
Naltrexone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000231	0.0007	CcSEcCtD
Naltrexone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00023	0.000697	CcSEcCtD
Naltrexone—UGT1A1—NRF2 pathway—GSTM1—urinary bladder cancer	0.00023	0.00391	CbGpPWpGaD
Naltrexone—Urticaria—Etoposide—urinary bladder cancer	0.000228	0.000691	CcSEcCtD
Naltrexone—Body temperature increased—Etoposide—urinary bladder cancer	0.000227	0.000688	CcSEcCtD
Naltrexone—Abdominal pain—Etoposide—urinary bladder cancer	0.000227	0.000688	CcSEcCtD
Naltrexone—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000227	0.000688	CcSEcCtD
Naltrexone—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000227	0.000688	CcSEcCtD
Naltrexone—Hepatitis—Epirubicin—urinary bladder cancer	0.000227	0.000686	CcSEcCtD
Naltrexone—Eye disorder—Methotrexate—urinary bladder cancer	0.000226	0.000685	CcSEcCtD
Naltrexone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000226	0.000685	CcSEcCtD
Naltrexone—Tinnitus—Methotrexate—urinary bladder cancer	0.000226	0.000684	CcSEcCtD
Naltrexone—Asthenia—Cisplatin—urinary bladder cancer	0.000225	0.000681	CcSEcCtD
Naltrexone—Pharyngitis—Epirubicin—urinary bladder cancer	0.000225	0.000681	CcSEcCtD
Naltrexone—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000225	0.000681	CcSEcCtD
Naltrexone—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000223	0.000674	CcSEcCtD
Naltrexone—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000221	0.000669	CcSEcCtD
Naltrexone—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000221	0.00375	CbGpPWpGaD
Naltrexone—Epistaxis—Doxorubicin—urinary bladder cancer	0.00022	0.000667	CcSEcCtD
Naltrexone—Angiopathy—Methotrexate—urinary bladder cancer	0.00022	0.000665	CcSEcCtD
Naltrexone—UGT1A1—Biological oxidations—GSTP1—urinary bladder cancer	0.00022	0.00373	CbGpPWpGaD
Naltrexone—Sinusitis—Doxorubicin—urinary bladder cancer	0.000219	0.000664	CcSEcCtD
Naltrexone—Immune system disorder—Methotrexate—urinary bladder cancer	0.000219	0.000662	CcSEcCtD
Naltrexone—Dizziness—Fluorouracil—urinary bladder cancer	0.000219	0.000662	CcSEcCtD
Naltrexone—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000218	0.000661	CcSEcCtD
Naltrexone—Chills—Methotrexate—urinary bladder cancer	0.000217	0.000658	CcSEcCtD
Naltrexone—UGT1A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000217	0.00368	CbGpPWpGaD
Naltrexone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000215	0.00065	CcSEcCtD
Naltrexone—Alopecia—Methotrexate—urinary bladder cancer	0.000214	0.000648	CcSEcCtD
Naltrexone—Vomiting—Gemcitabine—urinary bladder cancer	0.000214	0.000648	CcSEcCtD
Naltrexone—Mental disorder—Methotrexate—urinary bladder cancer	0.000212	0.000642	CcSEcCtD
Naltrexone—Rash—Gemcitabine—urinary bladder cancer	0.000212	0.000642	CcSEcCtD
Naltrexone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000212	0.000642	CcSEcCtD
Naltrexone—Eye disorder—Epirubicin—urinary bladder cancer	0.000212	0.000641	CcSEcCtD
Naltrexone—Hypersensitivity—Etoposide—urinary bladder cancer	0.000212	0.000641	CcSEcCtD
Naltrexone—Tinnitus—Epirubicin—urinary bladder cancer	0.000211	0.00064	CcSEcCtD
Naltrexone—Malnutrition—Methotrexate—urinary bladder cancer	0.000211	0.000638	CcSEcCtD
Naltrexone—Headache—Gemcitabine—urinary bladder cancer	0.000211	0.000638	CcSEcCtD
Naltrexone—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00021	0.000637	CcSEcCtD
Naltrexone—Vomiting—Fluorouracil—urinary bladder cancer	0.00021	0.000637	CcSEcCtD
Naltrexone—Hepatitis—Doxorubicin—urinary bladder cancer	0.00021	0.000635	CcSEcCtD
Naltrexone—Rash—Fluorouracil—urinary bladder cancer	0.000209	0.000631	CcSEcCtD
Naltrexone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000208	0.000631	CcSEcCtD
Naltrexone—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000208	0.00063	CcSEcCtD
Naltrexone—Headache—Fluorouracil—urinary bladder cancer	0.000207	0.000627	CcSEcCtD
Naltrexone—Dysgeusia—Methotrexate—urinary bladder cancer	0.000206	0.000625	CcSEcCtD
Naltrexone—Asthenia—Etoposide—urinary bladder cancer	0.000206	0.000624	CcSEcCtD
Naltrexone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000206	0.000624	CcSEcCtD
Naltrexone—Angiopathy—Epirubicin—urinary bladder cancer	0.000206	0.000623	CcSEcCtD
Naltrexone—Immune system disorder—Epirubicin—urinary bladder cancer	0.000205	0.00062	CcSEcCtD
Naltrexone—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000204	0.000619	CcSEcCtD
Naltrexone—Back pain—Methotrexate—urinary bladder cancer	0.000204	0.000618	CcSEcCtD
Naltrexone—Chills—Epirubicin—urinary bladder cancer	0.000203	0.000616	CcSEcCtD
Naltrexone—Pruritus—Etoposide—urinary bladder cancer	0.000203	0.000615	CcSEcCtD
Naltrexone—UGT1A1—Biological oxidations—GSTM1—urinary bladder cancer	0.000202	0.00343	CbGpPWpGaD
Naltrexone—Alopecia—Epirubicin—urinary bladder cancer	0.0002	0.000606	CcSEcCtD
Naltrexone—Nausea—Gemcitabine—urinary bladder cancer	0.0002	0.000605	CcSEcCtD
Naltrexone—Vomiting—Cisplatin—urinary bladder cancer	0.000199	0.000604	CcSEcCtD
Naltrexone—UGT1A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000199	0.00338	CbGpPWpGaD
Naltrexone—Vision blurred—Methotrexate—urinary bladder cancer	0.000199	0.000602	CcSEcCtD
Naltrexone—Mental disorder—Epirubicin—urinary bladder cancer	0.000199	0.000601	CcSEcCtD
Naltrexone—Rash—Cisplatin—urinary bladder cancer	0.000198	0.000599	CcSEcCtD
Naltrexone—Dermatitis—Cisplatin—urinary bladder cancer	0.000198	0.000598	CcSEcCtD
Naltrexone—Malnutrition—Epirubicin—urinary bladder cancer	0.000197	0.000597	CcSEcCtD
Naltrexone—Diarrhoea—Etoposide—urinary bladder cancer	0.000197	0.000595	CcSEcCtD
Naltrexone—Nausea—Fluorouracil—urinary bladder cancer	0.000196	0.000595	CcSEcCtD
Naltrexone—Eye disorder—Doxorubicin—urinary bladder cancer	0.000196	0.000593	CcSEcCtD
Naltrexone—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000196	0.000592	CcSEcCtD
Naltrexone—Tinnitus—Doxorubicin—urinary bladder cancer	0.000196	0.000592	CcSEcCtD
Naltrexone—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000195	0.000589	CcSEcCtD
Naltrexone—Flatulence—Epirubicin—urinary bladder cancer	0.000194	0.000589	CcSEcCtD
Naltrexone—Tension—Epirubicin—urinary bladder cancer	0.000194	0.000586	CcSEcCtD
Naltrexone—Dysgeusia—Epirubicin—urinary bladder cancer	0.000193	0.000585	CcSEcCtD
Naltrexone—Nervousness—Epirubicin—urinary bladder cancer	0.000192	0.00058	CcSEcCtD
Naltrexone—Back pain—Epirubicin—urinary bladder cancer	0.000191	0.000578	CcSEcCtD
Naltrexone—Angiopathy—Doxorubicin—urinary bladder cancer	0.00019	0.000576	CcSEcCtD
Naltrexone—Malaise—Methotrexate—urinary bladder cancer	0.00019	0.000576	CcSEcCtD
Naltrexone—Dizziness—Etoposide—urinary bladder cancer	0.00019	0.000575	CcSEcCtD
Naltrexone—Muscle spasms—Epirubicin—urinary bladder cancer	0.00019	0.000574	CcSEcCtD
Naltrexone—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000189	0.000574	CcSEcCtD
Naltrexone—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000189	0.000572	CcSEcCtD
Naltrexone—Chills—Doxorubicin—urinary bladder cancer	0.000188	0.00057	CcSEcCtD
Naltrexone—Nausea—Cisplatin—urinary bladder cancer	0.000186	0.000564	CcSEcCtD
Naltrexone—Vision blurred—Epirubicin—urinary bladder cancer	0.000186	0.000563	CcSEcCtD
Naltrexone—Alopecia—Doxorubicin—urinary bladder cancer	0.000185	0.000561	CcSEcCtD
Naltrexone—Cough—Methotrexate—urinary bladder cancer	0.000184	0.000557	CcSEcCtD
Naltrexone—Mental disorder—Doxorubicin—urinary bladder cancer	0.000184	0.000556	CcSEcCtD
Naltrexone—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000183	0.000554	CcSEcCtD
Naltrexone—Convulsion—Methotrexate—urinary bladder cancer	0.000183	0.000553	CcSEcCtD
Naltrexone—Vomiting—Etoposide—urinary bladder cancer	0.000183	0.000553	CcSEcCtD
Naltrexone—Malnutrition—Doxorubicin—urinary bladder cancer	0.000183	0.000553	CcSEcCtD
Naltrexone—Agitation—Epirubicin—urinary bladder cancer	0.000181	0.000549	CcSEcCtD
Naltrexone—Rash—Etoposide—urinary bladder cancer	0.000181	0.000548	CcSEcCtD
Naltrexone—Dermatitis—Etoposide—urinary bladder cancer	0.000181	0.000548	CcSEcCtD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000181	0.00307	CbGpPWpGaD
Naltrexone—Headache—Etoposide—urinary bladder cancer	0.00018	0.000545	CcSEcCtD
Naltrexone—Flatulence—Doxorubicin—urinary bladder cancer	0.00018	0.000545	CcSEcCtD
Naltrexone—Arthralgia—Methotrexate—urinary bladder cancer	0.000179	0.000543	CcSEcCtD
Naltrexone—Chest pain—Methotrexate—urinary bladder cancer	0.000179	0.000543	CcSEcCtD
Naltrexone—Myalgia—Methotrexate—urinary bladder cancer	0.000179	0.000543	CcSEcCtD
Naltrexone—Tension—Doxorubicin—urinary bladder cancer	0.000179	0.000542	CcSEcCtD
Naltrexone—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000179	0.000541	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000178	0.00054	CcSEcCtD
Naltrexone—Malaise—Epirubicin—urinary bladder cancer	0.000178	0.000539	CcSEcCtD
Naltrexone—Discomfort—Methotrexate—urinary bladder cancer	0.000177	0.000537	CcSEcCtD
Naltrexone—Nervousness—Doxorubicin—urinary bladder cancer	0.000177	0.000537	CcSEcCtD
Naltrexone—Syncope—Epirubicin—urinary bladder cancer	0.000177	0.000536	CcSEcCtD
Naltrexone—Back pain—Doxorubicin—urinary bladder cancer	0.000177	0.000535	CcSEcCtD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	0.000176	0.00298	CbGpPWpGaD
Naltrexone—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000176	0.000531	CcSEcCtD
Naltrexone—Palpitations—Epirubicin—urinary bladder cancer	0.000174	0.000528	CcSEcCtD
Naltrexone—Confusional state—Methotrexate—urinary bladder cancer	0.000173	0.000525	CcSEcCtD
Naltrexone—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000173	0.000525	CcSEcCtD
Naltrexone—Cough—Epirubicin—urinary bladder cancer	0.000172	0.000521	CcSEcCtD
Naltrexone—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000172	0.000521	CcSEcCtD
Naltrexone—Vision blurred—Doxorubicin—urinary bladder cancer	0.000172	0.000521	CcSEcCtD
Naltrexone—Convulsion—Epirubicin—urinary bladder cancer	0.000171	0.000518	CcSEcCtD
Naltrexone—Infection—Methotrexate—urinary bladder cancer	0.000171	0.000518	CcSEcCtD
Naltrexone—Nausea—Etoposide—urinary bladder cancer	0.000171	0.000517	CcSEcCtD
Naltrexone—Hypertension—Epirubicin—urinary bladder cancer	0.00017	0.000516	CcSEcCtD
Naltrexone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000169	0.000513	CcSEcCtD
Naltrexone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000169	0.000511	CcSEcCtD
Naltrexone—Arthralgia—Epirubicin—urinary bladder cancer	0.000168	0.000509	CcSEcCtD
Naltrexone—Chest pain—Epirubicin—urinary bladder cancer	0.000168	0.000509	CcSEcCtD
Naltrexone—Myalgia—Epirubicin—urinary bladder cancer	0.000168	0.000509	CcSEcCtD
Naltrexone—Agitation—Doxorubicin—urinary bladder cancer	0.000168	0.000508	CcSEcCtD
Naltrexone—Anxiety—Epirubicin—urinary bladder cancer	0.000167	0.000507	CcSEcCtD
Naltrexone—Skin disorder—Methotrexate—urinary bladder cancer	0.000167	0.000506	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000167	0.000505	CcSEcCtD
Naltrexone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000166	0.000504	CcSEcCtD
Naltrexone—Discomfort—Epirubicin—urinary bladder cancer	0.000166	0.000503	CcSEcCtD
Naltrexone—Malaise—Doxorubicin—urinary bladder cancer	0.000165	0.000498	CcSEcCtD
Naltrexone—Dry mouth—Epirubicin—urinary bladder cancer	0.000164	0.000497	CcSEcCtD
Naltrexone—Anorexia—Methotrexate—urinary bladder cancer	0.000164	0.000497	CcSEcCtD
Naltrexone—Syncope—Doxorubicin—urinary bladder cancer	0.000164	0.000496	CcSEcCtD
Naltrexone—Confusional state—Epirubicin—urinary bladder cancer	0.000162	0.000492	CcSEcCtD
Naltrexone—Palpitations—Doxorubicin—urinary bladder cancer	0.000161	0.000489	CcSEcCtD
Naltrexone—Oedema—Epirubicin—urinary bladder cancer	0.000161	0.000488	CcSEcCtD
Naltrexone—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000161	0.000488	CcSEcCtD
Naltrexone—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.00016	0.000486	CcSEcCtD
Naltrexone—Infection—Epirubicin—urinary bladder cancer	0.00016	0.000484	CcSEcCtD
Naltrexone—Cough—Doxorubicin—urinary bladder cancer	0.000159	0.000482	CcSEcCtD
Naltrexone—Shock—Epirubicin—urinary bladder cancer	0.000158	0.00048	CcSEcCtD
Naltrexone—Convulsion—Doxorubicin—urinary bladder cancer	0.000158	0.000479	CcSEcCtD
Naltrexone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000158	0.000478	CcSEcCtD
Naltrexone—Hypertension—Doxorubicin—urinary bladder cancer	0.000158	0.000477	CcSEcCtD
Naltrexone—Tachycardia—Epirubicin—urinary bladder cancer	0.000157	0.000476	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000157	0.000475	CcSEcCtD
Naltrexone—Skin disorder—Epirubicin—urinary bladder cancer	0.000156	0.000474	CcSEcCtD
Naltrexone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000156	0.000471	CcSEcCtD
Naltrexone—Insomnia—Methotrexate—urinary bladder cancer	0.000156	0.000471	CcSEcCtD
Naltrexone—Myalgia—Doxorubicin—urinary bladder cancer	0.000155	0.000471	CcSEcCtD
Naltrexone—Chest pain—Doxorubicin—urinary bladder cancer	0.000155	0.000471	CcSEcCtD
Naltrexone—Arthralgia—Doxorubicin—urinary bladder cancer	0.000155	0.000471	CcSEcCtD
Naltrexone—Anxiety—Doxorubicin—urinary bladder cancer	0.000155	0.000469	CcSEcCtD
Naltrexone—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	0.000155	0.00263	CbGpPWpGaD
Naltrexone—Paraesthesia—Methotrexate—urinary bladder cancer	0.000154	0.000468	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000154	0.000467	CcSEcCtD
Naltrexone—Discomfort—Doxorubicin—urinary bladder cancer	0.000154	0.000465	CcSEcCtD
Naltrexone—Anorexia—Epirubicin—urinary bladder cancer	0.000153	0.000465	CcSEcCtD
Naltrexone—Dyspnoea—Methotrexate—urinary bladder cancer	0.000153	0.000465	CcSEcCtD
Naltrexone—Somnolence—Methotrexate—urinary bladder cancer	0.000153	0.000463	CcSEcCtD
Naltrexone—Dry mouth—Doxorubicin—urinary bladder cancer	0.000152	0.00046	CcSEcCtD
Naltrexone—Confusional state—Doxorubicin—urinary bladder cancer	0.00015	0.000455	CcSEcCtD
Naltrexone—Decreased appetite—Methotrexate—urinary bladder cancer	0.00015	0.000453	CcSEcCtD
Naltrexone—Oedema—Doxorubicin—urinary bladder cancer	0.000149	0.000451	CcSEcCtD
Naltrexone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000149	0.000451	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000149	0.00045	CcSEcCtD
Naltrexone—Fatigue—Methotrexate—urinary bladder cancer	0.000148	0.000449	CcSEcCtD
Naltrexone—Infection—Doxorubicin—urinary bladder cancer	0.000148	0.000448	CcSEcCtD
Naltrexone—Pain—Methotrexate—urinary bladder cancer	0.000147	0.000446	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000147	0.000444	CcSEcCtD
Naltrexone—Shock—Doxorubicin—urinary bladder cancer	0.000147	0.000444	CcSEcCtD
Naltrexone—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000146	0.000442	CcSEcCtD
Naltrexone—Insomnia—Epirubicin—urinary bladder cancer	0.000146	0.000441	CcSEcCtD
Naltrexone—Tachycardia—Doxorubicin—urinary bladder cancer	0.000145	0.00044	CcSEcCtD
Naltrexone—Skin disorder—Doxorubicin—urinary bladder cancer	0.000145	0.000438	CcSEcCtD
Naltrexone—Paraesthesia—Epirubicin—urinary bladder cancer	0.000145	0.000438	CcSEcCtD
Naltrexone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000144	0.000436	CcSEcCtD
Naltrexone—Dyspnoea—Epirubicin—urinary bladder cancer	0.000144	0.000435	CcSEcCtD
Naltrexone—Somnolence—Epirubicin—urinary bladder cancer	0.000143	0.000433	CcSEcCtD
Naltrexone—Anorexia—Doxorubicin—urinary bladder cancer	0.000142	0.00043	CcSEcCtD
Naltrexone—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000142	0.000429	CcSEcCtD
Naltrexone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000141	0.000426	CcSEcCtD
Naltrexone—Decreased appetite—Epirubicin—urinary bladder cancer	0.00014	0.000424	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000139	0.000421	CcSEcCtD
Naltrexone—Fatigue—Epirubicin—urinary bladder cancer	0.000139	0.00042	CcSEcCtD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000138	0.00234	CbGpPWpGaD
Naltrexone—Pain—Epirubicin—urinary bladder cancer	0.000138	0.000417	CcSEcCtD
Naltrexone—Constipation—Epirubicin—urinary bladder cancer	0.000138	0.000417	CcSEcCtD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.000137	0.00233	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000137	0.00233	CbGpPWpGaD
Naltrexone—Urticaria—Methotrexate—urinary bladder cancer	0.000137	0.000414	CcSEcCtD
Naltrexone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000136	0.000412	CcSEcCtD
Naltrexone—Body temperature increased—Methotrexate—urinary bladder cancer	0.000136	0.000412	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000136	0.000411	CcSEcCtD
Naltrexone—Insomnia—Doxorubicin—urinary bladder cancer	0.000135	0.000408	CcSEcCtD
Naltrexone—UGT1A1—Metabolism—GSTZ1—urinary bladder cancer	0.000135	0.00229	CbGpPWpGaD
Naltrexone—OPRD1—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	0.000134	0.00229	CbGpPWpGaD
Naltrexone—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000134	0.000405	CcSEcCtD
Naltrexone—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000133	0.000402	CcSEcCtD
Naltrexone—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000133	0.000402	CcSEcCtD
Naltrexone—Somnolence—Doxorubicin—urinary bladder cancer	0.000132	0.000401	CcSEcCtD
Naltrexone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000132	0.000399	CcSEcCtD
Naltrexone—Decreased appetite—Doxorubicin—urinary bladder cancer	0.00013	0.000392	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000129	0.000389	CcSEcCtD
Naltrexone—Fatigue—Doxorubicin—urinary bladder cancer	0.000128	0.000389	CcSEcCtD
Naltrexone—Urticaria—Epirubicin—urinary bladder cancer	0.000128	0.000387	CcSEcCtD
Naltrexone—UGT1A1—Metabolism—NAT1—urinary bladder cancer	0.000128	0.00217	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTO2—urinary bladder cancer	0.000128	0.00217	CbGpPWpGaD
Naltrexone—Pain—Doxorubicin—urinary bladder cancer	0.000127	0.000386	CcSEcCtD
Naltrexone—Constipation—Doxorubicin—urinary bladder cancer	0.000127	0.000386	CcSEcCtD
Naltrexone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000127	0.000385	CcSEcCtD
Naltrexone—Body temperature increased—Epirubicin—urinary bladder cancer	0.000127	0.000385	CcSEcCtD
Naltrexone—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000127	0.000384	CcSEcCtD
Naltrexone—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000125	0.00212	CbGpPWpGaD
Naltrexone—Asthenia—Methotrexate—urinary bladder cancer	0.000123	0.000374	CcSEcCtD
Naltrexone—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000123	0.000372	CcSEcCtD
Naltrexone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000122	0.000369	CcSEcCtD
Naltrexone—Pruritus—Methotrexate—urinary bladder cancer	0.000122	0.000369	CcSEcCtD
Naltrexone—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000119	0.000359	CcSEcCtD
Naltrexone—Urticaria—Doxorubicin—urinary bladder cancer	0.000118	0.000358	CcSEcCtD
Naltrexone—OPRK1—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	0.000118	0.002	CbGpPWpGaD
Naltrexone—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000118	0.000357	CcSEcCtD
Naltrexone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000118	0.000357	CcSEcCtD
Naltrexone—Diarrhoea—Methotrexate—urinary bladder cancer	0.000118	0.000356	CcSEcCtD
Naltrexone—UGT1A1—Metabolism—UGT2B7—urinary bladder cancer	0.000117	0.00198	CbGpPWpGaD
Naltrexone—Asthenia—Epirubicin—urinary bladder cancer	0.000116	0.00035	CcSEcCtD
Naltrexone—Pruritus—Epirubicin—urinary bladder cancer	0.000114	0.000345	CcSEcCtD
Naltrexone—Dizziness—Methotrexate—urinary bladder cancer	0.000114	0.000345	CcSEcCtD
Naltrexone—OPRD1—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.000113	0.00193	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.00011	0.00187	CbGpPWpGaD
Naltrexone—Diarrhoea—Epirubicin—urinary bladder cancer	0.00011	0.000334	CcSEcCtD
Naltrexone—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00011	0.000332	CcSEcCtD
Naltrexone—Vomiting—Methotrexate—urinary bladder cancer	0.000109	0.000331	CcSEcCtD
Naltrexone—Rash—Methotrexate—urinary bladder cancer	0.000108	0.000329	CcSEcCtD
Naltrexone—Dermatitis—Methotrexate—urinary bladder cancer	0.000108	0.000328	CcSEcCtD
Naltrexone—Headache—Methotrexate—urinary bladder cancer	0.000108	0.000326	CcSEcCtD
Naltrexone—Asthenia—Doxorubicin—urinary bladder cancer	0.000107	0.000324	CcSEcCtD
Naltrexone—Dizziness—Epirubicin—urinary bladder cancer	0.000106	0.000322	CcSEcCtD
Naltrexone—OPRM1—TCR Signaling Pathway—HRAS—urinary bladder cancer	0.000106	0.00181	CbGpPWpGaD
Naltrexone—Pruritus—Doxorubicin—urinary bladder cancer	0.000105	0.000319	CcSEcCtD
Naltrexone—UGT1A1—Metabolism—CYP4B1—urinary bladder cancer	0.000105	0.00179	CbGpPWpGaD
Naltrexone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	0.000103	0.00176	CbGpPWpGaD
Naltrexone—Vomiting—Epirubicin—urinary bladder cancer	0.000102	0.00031	CcSEcCtD
Naltrexone—Nausea—Methotrexate—urinary bladder cancer	0.000102	0.000309	CcSEcCtD
Naltrexone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000102	0.000309	CcSEcCtD
Naltrexone—OPRD1—Signaling Pathways—HDAC4—urinary bladder cancer	0.000102	0.00173	CbGpPWpGaD
Naltrexone—Rash—Epirubicin—urinary bladder cancer	0.000102	0.000307	CcSEcCtD
Naltrexone—Dermatitis—Epirubicin—urinary bladder cancer	0.000101	0.000307	CcSEcCtD
Naltrexone—Headache—Epirubicin—urinary bladder cancer	0.000101	0.000305	CcSEcCtD
Naltrexone—OPRM1—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	9.96e-05	0.00169	CbGpPWpGaD
Naltrexone—OPRK1—G alpha (i) signalling events—CXCL8—urinary bladder cancer	9.94e-05	0.00169	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—SLC19A1—urinary bladder cancer	9.92e-05	0.00169	CbGpPWpGaD
Naltrexone—Dizziness—Doxorubicin—urinary bladder cancer	9.85e-05	0.000298	CcSEcCtD
Naltrexone—UGT1A1—Metabolism—PRSS3—urinary bladder cancer	9.66e-05	0.00164	CbGpPWpGaD
Naltrexone—Nausea—Epirubicin—urinary bladder cancer	9.56e-05	0.00029	CcSEcCtD
Naltrexone—Vomiting—Doxorubicin—urinary bladder cancer	9.47e-05	0.000287	CcSEcCtD
Naltrexone—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	9.43e-05	0.0016	CbGpPWpGaD
Naltrexone—Rash—Doxorubicin—urinary bladder cancer	9.39e-05	0.000284	CcSEcCtD
Naltrexone—Dermatitis—Doxorubicin—urinary bladder cancer	9.38e-05	0.000284	CcSEcCtD
Naltrexone—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	9.34e-05	0.00159	CbGpPWpGaD
Naltrexone—Headache—Doxorubicin—urinary bladder cancer	9.33e-05	0.000283	CcSEcCtD
Naltrexone—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	9.03e-05	0.00154	CbGpPWpGaD
Naltrexone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	9.02e-05	0.00153	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	9.01e-05	0.00153	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HDAC4—urinary bladder cancer	8.92e-05	0.00152	CbGpPWpGaD
Naltrexone—Nausea—Doxorubicin—urinary bladder cancer	8.85e-05	0.000268	CcSEcCtD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	8.77e-05	0.00149	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	8.61e-05	0.00146	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GLI1—urinary bladder cancer	8.52e-05	0.00145	CbGpPWpGaD
Naltrexone—OPRM1—G alpha (i) signalling events—CXCL8—urinary bladder cancer	8.4e-05	0.00143	CbGpPWpGaD
Naltrexone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	7.91e-05	0.00134	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—TYMP—urinary bladder cancer	7.73e-05	0.00131	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	7.63e-05	0.0013	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HDAC4—urinary bladder cancer	7.54e-05	0.00128	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GLI1—urinary bladder cancer	7.47e-05	0.00127	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	7.36e-05	0.00125	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NAT2—urinary bladder cancer	6.99e-05	0.00119	CbGpPWpGaD
Naltrexone—OPRD1—GPCR ligand binding—CXCL8—urinary bladder cancer	6.87e-05	0.00117	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	6.74e-05	0.00115	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	6.71e-05	0.00114	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	6.69e-05	0.00114	CbGpPWpGaD
Naltrexone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	6.68e-05	0.00114	CbGpPWpGaD
Naltrexone—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	6.56e-05	0.00112	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GLI1—urinary bladder cancer	6.32e-05	0.00107	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	6.17e-05	0.00105	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—RRM2—urinary bladder cancer	6.03e-05	0.00103	CbGpPWpGaD
Naltrexone—OPRK1—GPCR ligand binding—CXCL8—urinary bladder cancer	6.02e-05	0.00102	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	5.86e-05	0.000996	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTO2—urinary bladder cancer	5.85e-05	0.000995	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NAT1—urinary bladder cancer	5.85e-05	0.000995	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RBX1—urinary bladder cancer	5.84e-05	0.000993	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	5.79e-05	0.000984	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ENO2—urinary bladder cancer	5.59e-05	0.00095	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—HPGDS—urinary bladder cancer	5.59e-05	0.00095	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TSC1—urinary bladder cancer	5.49e-05	0.000934	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTT1—urinary bladder cancer	5.42e-05	0.000921	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	5.35e-05	0.00091	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JAG1—urinary bladder cancer	5.23e-05	0.000889	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RBX1—urinary bladder cancer	5.12e-05	0.000871	CbGpPWpGaD
Naltrexone—OPRM1—GPCR ligand binding—CXCL8—urinary bladder cancer	5.09e-05	0.000865	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.97e-05	0.000845	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	4.91e-05	0.000834	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	4.82e-05	0.000819	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TSC1—urinary bladder cancer	4.82e-05	0.000819	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	4.8e-05	0.000816	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JAG1—urinary bladder cancer	4.58e-05	0.00078	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	4.55e-05	0.000773	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NQO1—urinary bladder cancer	4.5e-05	0.000765	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PRSS3—urinary bladder cancer	4.43e-05	0.000754	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—RHOA—urinary bladder cancer	4.42e-05	0.000752	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.34e-05	0.000737	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RBX1—urinary bladder cancer	4.33e-05	0.000736	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—S100B—urinary bladder cancer	4.23e-05	0.00072	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.19e-05	0.000713	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.18e-05	0.000712	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TSC1—urinary bladder cancer	4.07e-05	0.000692	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—RHOA—urinary bladder cancer	4.01e-05	0.000682	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.99e-05	0.000679	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.88e-05	0.00066	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.88e-05	0.00066	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—RHOA—urinary bladder cancer	3.88e-05	0.000659	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JAG1—urinary bladder cancer	3.87e-05	0.000659	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NCOR1—urinary bladder cancer	3.81e-05	0.000647	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTP1—urinary bladder cancer	3.75e-05	0.000638	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—S100B—urinary bladder cancer	3.71e-05	0.000631	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—IL2—urinary bladder cancer	3.71e-05	0.000631	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TYMP—urinary bladder cancer	3.54e-05	0.000603	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—CXCL8—urinary bladder cancer	3.52e-05	0.000599	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—RHOA—urinary bladder cancer	3.52e-05	0.000598	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—TYMS—urinary bladder cancer	3.49e-05	0.000594	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.48e-05	0.000591	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GSTM1—urinary bladder cancer	3.45e-05	0.000587	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NCOR1—urinary bladder cancer	3.45e-05	0.000587	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.4e-05	0.000579	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.4e-05	0.000578	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL2—urinary bladder cancer	3.37e-05	0.000573	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TERT—urinary bladder cancer	3.36e-05	0.00057	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NCOR1—urinary bladder cancer	3.34e-05	0.000568	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—GPX1—urinary bladder cancer	3.3e-05	0.000562	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—RHOA—urinary bladder cancer	3.28e-05	0.000557	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—IL2—urinary bladder cancer	3.25e-05	0.000553	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—ERCC2—urinary bladder cancer	3.24e-05	0.000552	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.24e-05	0.000551	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.21e-05	0.000546	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NAT2—urinary bladder cancer	3.21e-05	0.000545	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—S100B—urinary bladder cancer	3.14e-05	0.000534	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL8—urinary bladder cancer	3.09e-05	0.000525	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FGFR3—urinary bladder cancer	3.08e-05	0.000524	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MTHFR—urinary bladder cancer	3.05e-05	0.000519	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ESR1—urinary bladder cancer	2.99e-05	0.000508	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—RHOA—urinary bladder cancer	2.97e-05	0.000506	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL2—urinary bladder cancer	2.95e-05	0.000502	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TERT—urinary bladder cancer	2.94e-05	0.0005	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.88e-05	0.000489	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.86e-05	0.000486	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NCOR1—urinary bladder cancer	2.82e-05	0.00048	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—RRM2—urinary bladder cancer	2.77e-05	0.00047	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL2—urinary bladder cancer	2.75e-05	0.000467	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGFR3—urinary bladder cancer	2.7e-05	0.000459	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ESR1—urinary bladder cancer	2.62e-05	0.000446	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CREBBP—urinary bladder cancer	2.62e-05	0.000446	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	2.61e-05	0.000444	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF1—urinary bladder cancer	2.59e-05	0.00044	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EGFR—urinary bladder cancer	2.58e-05	0.000438	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ENO2—urinary bladder cancer	2.56e-05	0.000436	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2.56e-05	0.000436	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL2—urinary bladder cancer	2.5e-05	0.000424	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TERT—urinary bladder cancer	2.49e-05	0.000423	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTT1—urinary bladder cancer	2.49e-05	0.000423	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARG—urinary bladder cancer	2.47e-05	0.00042	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—KRAS—urinary bladder cancer	2.43e-05	0.000414	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CREBBP—urinary bladder cancer	2.38e-05	0.000404	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—RHOA—urinary bladder cancer	2.37e-05	0.000403	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.33e-05	0.000396	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CREBBP—urinary bladder cancer	2.3e-05	0.000391	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGFR3—urinary bladder cancer	2.28e-05	0.000388	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1—urinary bladder cancer	2.27e-05	0.000386	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EGFR—urinary bladder cancer	2.26e-05	0.000384	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ESR1—urinary bladder cancer	2.22e-05	0.000377	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ERBB2—urinary bladder cancer	2.2e-05	0.000373	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—KRAS—urinary bladder cancer	2.13e-05	0.000363	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL8—urinary bladder cancer	2.08e-05	0.000354	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—RHOA—urinary bladder cancer	2.08e-05	0.000354	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—HRAS—urinary bladder cancer	2.07e-05	0.000352	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.07e-05	0.000351	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2—urinary bladder cancer	1.99e-05	0.000338	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—urinary bladder cancer	1.95e-05	0.000331	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CREBBP—urinary bladder cancer	1.94e-05	0.00033	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCND1—urinary bladder cancer	1.94e-05	0.00033	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ERBB2—urinary bladder cancer	1.92e-05	0.000327	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1—urinary bladder cancer	1.92e-05	0.000326	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EGFR—urinary bladder cancer	1.91e-05	0.000325	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—urinary bladder cancer	1.88e-05	0.00032	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.88e-05	0.000319	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTEN—urinary bladder cancer	1.87e-05	0.000318	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL8—urinary bladder cancer	1.83e-05	0.00031	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—HRAS—urinary bladder cancer	1.81e-05	0.000308	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—KRAS—urinary bladder cancer	1.8e-05	0.000307	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EP300—urinary bladder cancer	1.79e-05	0.000304	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—RHOA—urinary bladder cancer	1.76e-05	0.000299	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2—urinary bladder cancer	1.74e-05	0.000297	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SRC—urinary bladder cancer	1.74e-05	0.000295	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.72e-05	0.000293	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCND1—urinary bladder cancer	1.7e-05	0.000289	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTEN—urinary bladder cancer	1.7e-05	0.000288	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—urinary bladder cancer	1.65e-05	0.000281	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.65e-05	0.00028	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTEN—urinary bladder cancer	1.64e-05	0.000279	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ERBB2—urinary bladder cancer	1.63e-05	0.000277	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—EP300—urinary bladder cancer	1.62e-05	0.000275	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.6e-05	0.000272	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.58e-05	0.000269	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.58e-05	0.000269	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EP300—urinary bladder cancer	1.57e-05	0.000266	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MYC—urinary bladder cancer	1.56e-05	0.000264	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL8—urinary bladder cancer	1.54e-05	0.000262	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—HRAS—urinary bladder cancer	1.53e-05	0.000261	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SRC—urinary bladder cancer	1.52e-05	0.000259	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGFR—urinary bladder cancer	1.52e-05	0.000259	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.52e-05	0.000258	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.49e-05	0.000253	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2—urinary bladder cancer	1.47e-05	0.000251	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KRAS—urinary bladder cancer	1.44e-05	0.000244	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCND1—urinary bladder cancer	1.44e-05	0.000244	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.4e-05	0.000238	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—urinary bladder cancer	1.4e-05	0.000237	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.39e-05	0.000236	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTEN—urinary bladder cancer	1.39e-05	0.000236	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MYC—urinary bladder cancer	1.36e-05	0.000232	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGFR—urinary bladder cancer	1.33e-05	0.000227	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EP300—urinary bladder cancer	1.32e-05	0.000225	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SRC—urinary bladder cancer	1.29e-05	0.000219	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—urinary bladder cancer	1.28e-05	0.000217	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KRAS—urinary bladder cancer	1.26e-05	0.000214	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—HRAS—urinary bladder cancer	1.22e-05	0.000208	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MYC—urinary bladder cancer	1.15e-05	0.000196	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.13e-05	0.000193	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGFR—urinary bladder cancer	1.13e-05	0.000192	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—urinary bladder cancer	1.12e-05	0.00019	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.09e-05	0.000185	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HRAS—urinary bladder cancer	1.07e-05	0.000182	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KRAS—urinary bladder cancer	1.07e-05	0.000181	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—urinary bladder cancer	9.47e-06	0.000161	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HRAS—urinary bladder cancer	9.05e-06	0.000154	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—urinary bladder cancer	8.92e-06	0.000152	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTEN—urinary bladder cancer	7.78e-06	0.000132	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—EP300—urinary bladder cancer	7.42e-06	0.000126	CbGpPWpGaD
